Protocol Ledger

NCT07475806 · Phase II · RECRUITING

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Interventional Phase II clinical trial protocol NCT07475806 sponsored by Astellas Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-12 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07475806
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07475806
Protocol FieldVerified Registry Value
NCT IdentifierNCT07475806
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2026-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI